Papers

Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis

Djillali Annane, Eric Bellissant, Pierre Edouard Bollaert, Josef Briegel, Didier Keh, Yizhak Kupfer

Abstract

Objective To assess the effects of corticosteroids on mortality in patients with severe sepsis and septic shock.

Data sources Randomised and quasi-randomised trials of corticosteroids versus placebo (or supportive treatment alone) retrieved from the Cochrane infectious diseases group's trials register, the Cochrane central register of controlled trials, Medline, Embase, and LILACS.

Review method Two pairs of reviewers agreed on eligibility of trials. One reviewer entered data on to the computer and four reviewers checked them. We obtained some missing data from authors of trials and assessed methodological quality of trials.

Results 16/23 trials (n=2063) were selected. Corticosteroids did not change 28 day mortality (15 trials, n=2022; relative risk 0.92, 95% confidence interval 0.75 to 1.14) or hospital mortality (13 trials, n=1418; 0.89, 0.71 to 1.11). There was significant heterogeneity. Subgroup analysis on long courses (≥ 5 days) with low dose (≤ 300 mg hydrocortisone or equivalent) corticosteroids showed no more heterogeneity. The relative risk for mortality was 0.80 at 28 days (five trials, n=465; 0.67 to 0.95) and 0.83 at hospital discharge (five trials, n=465, 0.71 to 0.97). Use of corticosteroids reduced mortality in intensive care units (four trials, n=425, 0.83, 0.70 to 0.97), increased shock reversal at 7 days (four trials, n=425; 1.60, 1.27 to 2.03) and 28 days (four trials, n=425, 1.26, 1.04 to 1.52) without inducing side effects.

Conclusions For all trials, regardless of duration of treatment and dose, use of corticosteroids did not significantly affect mortality. With long courses of low doses of corticosteroids, however, mortality at 28 days and hospital mortality was reduced.

Introduction

Each year severe sepsis occurs in about three people per 1000 population and accounts for 2% of hospital stays.¹ About 3% of such patients will develop septic shock,² which itself accounts for 10% of stays in intensive care units.³ Overall, hospital mortality is 30% for severe sepsis and 50-60% for septic shock.¹⁻³

Researchers have explored the biological mechanisms of septic shock for potential interventions. Corticosteroids have been tested because of their interactions with immune responses.⁴ Indeed, these hormones affect inflammation through their effects on white blood cells, cytokines, and nitric oxide production. However, cytokines may suppress the cortisol response to the adrenocorticotropin hormone, causing poor adrenal activity,⁵ and body tissues may become resistant to corticosteroids.⁶ The prevalence of adrenal insufficiency in septic shock is about 50%. For these reasons, it has been anticipated that corticosteroids could be beneficial in septic shock.

Initial studies with corticosteroids in sepsis and septic shock used short courses of high doses. They did not show any evidence of benefit, as shown by two meta-analyses of the randomised trials published during the period 1966-93.^{7,8} However, these reviews did not exclude a benefit of longer durations of treatment (≥ 5 days) and lower doses (≤ 300 mg hydrocortisone or equivalent a day), as observed in more recent trials.⁹⁻¹⁴ We systematically reanalysed the effects of corticosteroids in severe sepsis and septic shock, considering all currently available data.

Methods

Studies and participants

We searched for randomised or quasi-randomised trials, with or without blinding, on severe sepsis and septic shock in children or adults.¹⁵ We included data from trials in sepsis, sepsis syndrome, or acute respiratory distress syndrome if separate data were available for septic shock.

Interventions

We considered all studies reporting on intravenous treatment with any corticosteroid preparation (for example, cortisone, hydrocortisone, methylprednisolone, betamethasone, or dexamethasone). We defined length of treatment at full doses as long (≥ 5 days) or short (< 5 days) and classified daily doses of corticosteroids as low (≤ 300 mg of hydrocortisone or equivalent) or high (> 300 mg).

The control group received a standard treatment (that is, antibiotics, fluid replacement, inotropes or vasopressors, mechanical ventilation, renal replacement therapy), given either alone or with a placebo.

Table 1 Characteristics of studies excluded from meta-analysis of corticosteroids for patients with severe sepsis or septic shock

Study	Reason for exclusion
Hahn 1951 ¹⁸	Patients with acute streptococcal infections but not septic shock. Trial investigated effect of hydrocortisone on fever, anti-streptolysin titres, and onset of rheumatic fever. No data are reported for analysis of various outcomes considered in systematic review
Hughes 1984 ²⁶	Only acute effects (within 1 hour) of methylprednisolone and/or naloxone on haemodynamic data were available, and no data reported for any outcomes considered in systematic review
McKee 1983 ²⁵	Mixed population of critically ill patients. Separate data from septic shock not available
Meduri 1998 ³⁴	Trial included patients with late acute respiratory distress syndrome phase and not patients with septic shock
Rogers 1970 ²¹	Study published only as abstract, no contact with authors possible, incomplete information for primary and secondary outcomes
Thompson 1976 ¹²	Study published only as abstract, no contact with authors possible, incomplete information for primary and secondary outcomes
Weigelt 1985 ²⁹	Mixed population of critically ill patients. Separate data from septic shock not available

Papers

Table 2 Characteristics of included randomised controlled trials

Study	Design	Patients	Interventions	Outcomes
Annane 2002 ¹² (France)	2 parallel groups, 19 centres	300 adults with vasopressor and ventilator dependent septic shock	Hydrocortisone (50 mg intravenous bolus every 6 h for 7 days + fludrocortisone 50 µg taken orally every 24 h for 7 days); respective placebos. Treatments had to be initiated within 8 h from shock onset	Primary: 28 day mortality in non-responders Secondary: 28 day mortality in responders and all patients; ICU mortality; hospital mortality; 1 year mortality; shock reversal; organ system failure free days; safety
Bollaert 1998 ⁹ (France)	2 parallel groups, 2 centres	41 adults with vasopressor and ventilator dependent septic shock	Hydrocortisone (100 mg intravenous bolus every 8 h for 5 d then tapered over 6 d); placebo. Treatments had to be initiated after 48 h or more from shock onset	Primary: shock reversal Secondary: 28 day mortality; improvement in haemodynamics; safety
Bone 1987 ³⁰ (US)	2 parallel groups, 19 centres	382 adults with severe sepsis (n=234) or septic shock (n=148)	Methylprednisolone (30 mg/kg 20 min intravenous infusion, every 6 h for 24 h); placebo. Treatments had to be initiated 2 h from time entry criteria were met	Primary: 14 day development of shock for severe sepsis; shock reversal for septic shock; 14 day death and safety
Briegel 1999 ¹⁰ (Germany)	2 parallel groups, 1 centre	40 adults with vasopressor and ventilator dependent septic shock	Hydrocortisone (100 mg 30 min intravenous infusion followed by 0.18 mg/kg/h continuous infusion until shock reversal and then tapered off); placebo. Treatments had to be initiated within 72 h from shock onset	Primary: shock reversal Secondary: 28 day mortality; improvement in haemodynamics; organ system failure; safety
Chawla 1999 ¹¹ (US)	2 parallel groups, 1 centre	44 adults with vasopressor dependent septic shock	Hydrocortisone (100 mg intravenous bolus every 8 h for 3 days then tapered over 4 days); placebo. Treatments had to be initiated after 72 h or more from shock onset	Primary: shock reversal Secondary: 28 day mortality; improvement in haemodynamics; safety
CSG 1963 ²⁰ (US)	2 parallel groups, 5 centres	194 adults and 135 children with vasopressor dependent septic shock	Hydrocortisone (intravenous infusion of 300 mg for 24 h then 250 mg for 24 h, followed by 200 mg orally on day 3, then tapered off in steps of 50 mg/day—that is, total duration of treatment 6 days); placebo	Primary: hospital mortality Secondary: safety
Keh 2003 ¹⁴ (Germany)	Crossover design	40 adults with vasopressor dependent septic shock	Hydrocortisone (100 mg 30 min intravenous infusion followed by 10 mg/h continuous infusion for 3 days); placebo. All patients received hydrocortisone for 3 days preceded or followed by placebo for 3 days	Primary: immune response. Secondary: improvement in haemodynamics and organ system failure; safety
Klastersky ²³ 1971 (Belgium)	2 parallel groups, 1 centre	85 adults with disseminated cancer and life threatening infection	Betamethasone (1 mg/kg/day in 2 intravenous doses for 3 consecutive days); placebo	30 day mortality; rate of adverse events
Lucas 1984 ²⁷ (US)	2 parallel groups, 1 centre	48 adults with septic shock	Dexamethasone (2 mg/kg as a single intravenous bolus followed a maintenance infusion of 2 mg/kg/24 h for 2 days); standard treatment	Primary: 14 day mortality (unclear) Secondary: improvement in haemodynamics; improvement in pulmonary function; safety
Luce 1988 ³²	2 parallel groups, 1 centre	75 adults with septic shock	Methylprednisolone (30 mg/kg 15 min intravenous infusion, every 6 h for 24 h); placebo	Primary: prevention of acute respiratory distress syndrome Secondary: hospital mortality
Schumer 1976 ²⁴ (US)	3 parallel groups, 1 centre	172 adults with septic shock with positive blood cultures	Dexamethasone (3 mg/kg as a single intravenous bolus); methylprednisolone (30 mg/kg as a single intravenous bolus); placebo. Treatments might have been repeated once after 4 h and had to be initiated at time of diagnosis	Primary: 28 day mortality Secondary: complications rates
Slusher 1996 ³³ (US, Kenya, Nigeria)	2 Parallel groups, 2 centres	72 African children aged 1 to 16 years with severe sepsis or septic shock	Dexamethasone (0.20 mg/kg every 8 h for 2 days); placebo. Treatments might have been repeated once after 4 h if shock persisted and had to be initiated 5-10 min before first dose of antibiotic	Primary: hospital mortality (unclear) Secondary: haemodynamic stability at 48 h; complications
Sprung 1984 ²⁸ (US)	3 parallel groups, 2 centres	59 adults with vasopressor dependent septic shock	Dexamethasone (6 mg/kg as a single intravenous 10 to 15 min infusion); methylprednisolone (30 mg/kg as a single intravenous 10 to 15min infusion); no treatment; placebo. Treatments might have been repeated once after 4 h if shock persisted and had to be initiated at time of diagnosis	Primary: hospital mortality; shock reversal Secondary: complications of septic shock; treatments' safety
VASSCSG 1987 ³¹ (US)	2 parallel groups, 10 centres.	223 adults with severe sepsis or septic shock (n=100)	Methylprednisolone (30 mg/kg as a single intravenous 10-15 min infusion, followed by a constant infusion of 5 mg/kg/h for 9 h); placebo. Treatments had to be initiated within 2 h	Primary: 14 day mortality Secondary: complications
Wagner 1955 ¹⁹ (US)*	2 parallel groups, 2 centres	113 adults with pneumococcal pneumonia; shock present in only 3	Hydrocortisone (orally 80 mg on admission followed by 60 mg 3 times on day 1, then 40 mg 4 times on day 2, 20 mg 4 times on day 3, 10 mg 4 times on day 4, and 10 mg twice on day 5); standard therapy (first 85 patients); placebo (last 28 patients)	Fever; pleuritic pains; patient's wellbeing
Yildiz 2002 ¹³ (Turkey)	2 parallel groups, 1 centre	40 adults with sepsis (n=14), severe sepsis (n=17), and septic shock (n=9)	Prednisolone (2 intravenous bolus, 5 mg at 6 am and 2.5 mg at 18 pm for 10 days); placebo	Primary: 28 day mortality Secondary: complications

CSG=Cooperative Study Group; VASSCSG=Veterans Administration Systemic Sepsis Cooperative Study Group.

*Quasi-randomised.

Table 3 Assessment of methodological quality of studies with Cronin et al's "methodologic quality form"^{*,8}

Study	1	2	3	4	5	6	7	8	9	10	11	Total (14.50)
Wagner 1955 ¹⁹	0.5	0.5	1	0	2	0	0	0.5	0	0	0	4.5
CSG 1963 ²⁰	0	0	2	0	2	0	0	0.5	0	0	0	4.5
Klasterski 1971 ²³	0	0.5	2	2	2	0	1	0	0	0	0.5	8.0
Schumer 1976 ²⁴	0.5	0.5	1	0	2	0	1	0.5	0	0	0.5	6.0
Lucas 1984 ²⁷	0	0.5	1	0	2	0	1	0	1	0	0.5	6.0
Sprung 1984 ²⁸	0.5	1	2	0	2.5	0	1	0.5	0	0	1	8.5
Bone 1987 ³⁰	0.5	1	2	2	2.5	0	1	0.5	0	1	0.5	11.0
VASSCSG 1987 ³¹	1	1	2	2	2.5	1	1	1	1	1	0.5	14.0
Luce 1988 ³²	1	1	2	2	2.5	0	1	1	0	0.5	0.5	11.5
Slusher 1996 ³³	0.5	1	2	2	2.5	0	1	0.5	0	0	0.5	10
Bollaert 1998 ⁹	0.5	1	2	2	2.5	1	1	1	1	1	1	14
Briegel 1999 ¹⁰	0.5	1	2	2	2.5	1	1	1	1	1	1	14
Chawla 1999 ¹¹	0.5	1	2	2	2.5	1	1	0.5	0	1	1	12.5
Anname 2002 ¹²	1	1	2	2	2.5	1	1	1	1	1	1	14.5
Yildiz 2002 ¹³	0.5	1	2	2	2.5	0	1	0.5	0	0	0.5	10
Keh 2003 ¹⁴	0.5	1	2	2	2.5	1	1	1	1	1	1	14

CSG=Cooperative Study Group; VASSCSG=Veterans Administration Systemic Sepsis Cooperative Study Group.

*Assessment of quality with scores in parentheses. 1=Patient selection: all eligible patients with number of and reason for exclusions given (1); attempt to do so, but reasons for failure and exclusion not given (0.5); selected patients/eligible patients not described (0). 2=Patients characteristics at baseline: diagnosis/similar distribution between groups reported (0.50), not reported (0); severity of illness <10% difference between groups reported (0.50), not reported (0). 3=Randomisation: concealed randomisation (computer, centralised, etc (2); potentially manipulable (sealed envelope, date of admission, medical records, birth date, etc (1); can't tell (0). 4=Blinding: double blind (at least 2 of physicians, outcome analyst, patients) (2); single blinded (1); unblinded/can't tell (0). 5=Intervention: drug described explicitly—yes (0.50), no (0); dosing regimen (dose, frequency) reported (0.50), not reported (0); onset of treatment after development of sepsis reported (0.50), not reported (0); duration of treatment reported (0.50), not reported (0); placebo reported (0.50), not reported (0). 6=Contamination: reported (1), not reported (0). 7=Cointervention: reported (1); not reported (0). 8=Explicit description of complications: any three of secondary infection, gastroduodenal bleeding, organ system failure, hyperglycaemia (1); any two of those complications (0.5); 1 complication or none (0). 9=Withdrawal: described number and reason for withdrawal (1); described one of above (0.50); described neither (0). 10=Intention to treat and adherence to protocol: both reported (1), one reported (0.50), none reported (0). 11=Explicit definition: of septic shock (vasopressors dependence) (1); of sepsis only (consensus criteria) (0.50); none (0).

Outcome measures

The primary outcome measure was all cause mortality at 28 days. Secondary outcome measures included mortality in the intensive care unit and in hospital, number of patients with reversal of shock (that is, stable haemodynamic status for at least 24 hours after patients are weaned from vasopressors) at 7 and 28 days, and number of patients with adverse events (for instance, gastroduodenal bleeding, superinfections, hyperglycaemia, and other adverse effects).

Search strategy for identification of studies

We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, either in press or in progress). We searched the Cochrane infectious diseases group's trials register for relevant trials up to August 2003 using the search terms sepsis and septic shock as described in the Cochrane Library (issue 3, 2003). We searched the Cochrane central register of controlled trials (Cochrane Library, issue 3, 2003) using the search terms sepsis, septic shock, steroids, and corticosteroids; Medline (1966 to August 2003) using the search terms sepsis, septic shock, steroids, corticosteroids, adrenal cortex hormones, and glucocorticoids; Embase

(1974 to August 2003) using the search terms sepsis, septic shock, steroids, and corticosteroids; and LILACS (to August 2003) using the search terms sepsis, steroids, and corticosteroids.¹⁶ We also checked the reference lists of resulting trials and, when possible, contacted authors to identify any additional published or unpublished data.

Study selection

One reviewer (DA) checked all identified titles and abstracts, and three reviewers (PEB, JB, and DK) validated this check. Two pairs of reviewers (DA/PEB and JB/DK) examined all potential trials, selected eligible trials, and graded their methodological quality. Any disagreement within or between pairs was resolved by discussion within the four reviewers. We contacted authors for clarification when necessary.

Assessment of methodological quality

We documented the methodological quality of trials using a previously published score,⁸ and we graded generation of allocation sequence and allocation concealment as adequate, unclear, or inadequate.¹⁷ Methods for blinding were considered as double blind (neither patients nor care providers or assessors knew

Table 4 Assessment of methodological quality of studies with method recommended by Cochrane Infectious Diseases Group

	Adequate	Inadequate	Unclear
Generation of allocation concealment	CSG 1963, Klasterski 1971, Sprung 1984, Bone 1987, VASSCSG 1987, Luce 1988, Slusher 1996, Bollaert 1998, Briegel 1999, Chawla 1999, Annane 2002, Yildiz 2002, Keh 2003	Wagner 1955, Schumer 1976, Lucas 1984	None
Allocation concealment	CSG 1963, Klasterski 1971, Bone 1987, VASSCSG 1987, Luce 1988, Slusher 1996, Bollaert 1998, Briegel 1999, Chawla 1999, Annane 2002, Yildiz 2002, Keh 2003	Wagner 1955, Schumer 1976, Lucas 1984, Sprung 1984	None
Blinding	Klasterski 1971, Bone 1987, VASSCSG 1987, Luce 1988, Slusher 1996, Bollaert 1998, Briegel 1999, Chawla 1999, Annane 2002, Yildiz 2002, Keh 2003	Wagner 1955, CSG 1963, Schumer 1976, Lucas 1984, Sprung 1984	None
Lost to follow up	Lucas 1984, VASSCSG 1987, Bollaert 1998, Briegel 1999, Annane 2002, Keh 2003	None	Wagner 1955, CSG 1963, Klasterski 1971, Schumer 1976, Sprung 1984, Bone 1987, Luce 1988, Slusher 1996, Chawla 1999, Yildiz 2002

CSG = Cooperative Study Group; VASSCSG = Veterans Administration Systemic Sepsis Cooperative Study Group.

Fig 1 Effects of corticosteroids on all cause mortality at 28 days in patients with severe sepsis and septic shock

which treatment was given), single blind (either patients or care providers or assessors were aware of treatment), and open (all parties were aware of treatment). Loss to follow up was described as adequate (analysis included $\geq 90\%$ of patients), unclear (not reported), and inadequate (analysis included $< 90\%$ of patients). Any disagreement within or between pairs was resolved by discussion within the four reviewers. We contacted authors for clarification when necessary.

Data extraction

One reviewer (DA) drew up a standard data extraction form and the other reviewers (PEB, JB, DK, and YK) validated it. Four reviewers (DA, PEB, JB, and DK) then independently extracted data and contacted authors of trials for missing data when

possible. One reviewer (DA) entered data on to the computer, and four reviewers (PEB, JB, DK, and YK) checked them.

Data analyses

For each outcome measure, we computed 2×2 tables summarising, in each treatment group, the number of patients with the outcome and the total number of patients, and we organised the data so that a relative risk < 1.0 favoured corticosteroids (except for shock reversal at days 7 and 28, for which > 1.0 favoured corticosteroids). We performed intention to treat analyses. All statistical calculations used Review Manager 4.2. We calculated a weighted treatment effect (using fixed effects model) across trials. The results were expressed as relative risks with 95% confidence intervals. We considered using random effects model only in case of heterogeneity (that is, $P \leq 0.10$ for χ^2 test for heterogeneity).

Fig 2 Effects of corticosteroids on mortality in intensive care unit in patients with severe sepsis and septic shock

Potential sources of heterogeneity were identified by sensitivity analyses on the basis of high quality trials and by subgroup analysis on the basis of long courses of low dose corticosteroids. This analysis allowed us to evaluate the

strategy based on the high prevalence of adrenal insufficiency in septic shock and tested in trials performed after 1992.⁹⁻¹⁴ We sought evidence of publication bias using the funnel plot method.¹⁶

Fig 3 Effects of corticosteroids on mortality in hospital in patients with severe sepsis and septic shock

Fig 4 Effects of corticosteroids on shock reversal in patients with severe sepsis and septic shock

Results

Description of studies

We identified 23 trials on corticosteroids in severe sepsis or septic shock.^{9-14 18-34} Of these, we excluded seven (table 1)^{18 21 22 25 26 29 34} and included 16 trials (n=2063) (table 2). For six trials (n=524) we extracted data from both published and unpublished sources.^{9-12 14 28} For one trial, contact with authors did not provide any additional information.³² For the nine other trials the primary investigators could not be contacted.^{13 19 20 23 24 27 30 31 33} Tables 3 and 4 give details of the studies included.

All cause mortality at 28 days

We extracted data for all cause mortality at 28 days from 15 trials (n=2022) (fig 1). There were 351/1033 (34%) deaths in the treated group compared with 329/989 (33%) in the control group. There was significant heterogeneity in the results ($\chi^2=33.09$, $P=0.003$). The relative risk of dying at 28 days was 0.92 (95% confidence interval 0.75 to 1.14, $P=0.46$; random effects model).

The subgroup analysis on five trials (n=465) with long courses of low dose corticosteroids no longer showed heterogeneity across the trials, and the all cause mortality at 28 days was lower (0.80, 0.67 to 0.95, $P=0.01$). In contrast, the subgroup analysis on eight trials (n=1115) with short courses of high dose corticosteroids did not show any difference (0.97, 0.72 to 1.31, $P=0.84$; random effects model). Subgroup analyses based on high quality trials had a relative risk near 1.0 and failed to explain heterogeneity (data not shown).

Mortality in intensive care unit

We extracted data for mortality in intensive care units from four trials (n=425), all of which investigated the effects of long courses of low dose corticosteroids (fig 2). There were 108/216 (50%) deaths in the intensive care unit in the treated group compared with 127/209 (61%) in the control group (0.83, 0.70 to 0.97, $P=0.02$).

Mortality in hospital

We extracted data for hospital mortality from 13 trials (n=1418) (fig 3). There were 279/730 (38%) hospital deaths in the treated group compared with 271/688 (39%) in the control group. There was significant heterogeneity in the results ($\chi^2=27.68$, $P=0.006$). The relative risk of dying in hospital was 0.89 (0.71 to 1.11, $P=0.30$; random effects model).

The subgroup analysis on five trials (n=465) with long courses of low dose corticosteroids no longer showed heterogeneity across the trials and showed reduced mortality in hospital (0.83, 0.71 to 0.97, $P=0.02$). In contrast, the subgroup analysis on six trials (n=511) with short courses of high dose corticosteroids did not show any difference in hospital mortality (0.89, 0.57 to 1.37, $P=0.59$; random effects model). Subgroup analyses based on high quality trials had a relative risk near 1.0 and failed to explain heterogeneity (data not shown).

Fig 5 Adverse effects of corticosteroids in patients with severe sepsis and septic shock

Shock reversal at day 7

We extracted data for shock reversal at day 7 from six trials ($n=728$) (fig 4). There were 218/389 (56%) shock reversals at day 7 in the treated group compared with 154/339 (45%) in the control group (1.43, 1.01 to 2.01, $P=0.04$; random effects model). There was significant heterogeneity in the results ($\chi^2=20.38$, $P=0.001$).

The subgroup analysis on four trials ($n=425$) with long courses of low dose corticosteroids no longer showed heterogeneity across the trials, and showed increased rate of shock reversals at 7 days (108/216 (50%) *v* 65/209 (31%); 1.60, 1.27 to 2.03, $P<0.0001$).

Shock reversal at day 28

We extracted data for shock reversal at day 28 from four trials ($n=425$) (fig 4). There were 117/216 (54%) shock reversals at

day 28 in the treated group compared with 90/209 (43%) in the control group (1.26, 1.04 to 1.52, $P=0.02$).

Adverse events

There was no evidence that corticosteroids increased the risk of gastroduodenal bleeding (10 trials, $n=1321$; 1.16, 0.82 to 1.65, $P=0.40$), superinfections (12 trials, $n=1705$; 0.93, 0.73 to 1.18, $P=0.54$), or hyperglycaemia (6 trials, $n=608$; 1.22, 0.84 to 1.78, $P=0.30$) (fig 5). Only one trial reported the definition for hyperglycaemia,³² the others reporting only the number of patients with hyperglycaemia. Another trial reported a significant rise in serum sodium concentration (>155 mmol/l) in 6/20 (30%) patients in the treated group and in 1/20 (5%) patients in the placebo group.¹⁰

Discussion

When we considered all the trials included in this systematic review, regardless of duration of treatment and dose, we found no evidence of a beneficial effect of corticosteroids on all cause mortality at 28 days and mortality in hospital from severe sepsis and septic shock. However, for both outcomes, the results showed strong heterogeneity that was not explained by the quality of the trials. For both outcomes, sorting the trials by year of publication showed that before 1992 almost all trials showed a relative risk of dying >1.0 , whereas after 1992 all trials had a relative risk of dying <1.0 . This date coincides with the consensus definition for sepsis¹⁵ and with the observation that septic shock is often complicated by adrenal insufficiency.³⁵ The trials conducted before 1992 probably included patients with a heterogeneous risk of death, while the trials designed after 1992 focused on a more homogeneous population of patients with septic shock. More recent trials also used long courses of low dose corticosteroids, with the aim of treating adrenal insufficiency^{5, 35} or because of cortisol tissue resistance.⁶ The preferred drug was hydrocortisone, with doses of 200-300 mg used to reproduce the cortisol concentrations achieved at maximum exercise in healthy people.^{9, 10, 14} Treatment lasted about a week, corresponding roughly to the mean time that patients with septic shock take vasopressors. Sensitivity analyses of these trials showed significant reduction in all cause mortality at 28 days and mortality in hospital. Long courses of low dose corticosteroids also reduced mortality in intensive care units.

Improvement in survival with corticosteroids may result from reduced duration of shock (as shown by the higher proportions of shock reversal at days 7 and 28), severity of inflammation,¹⁴ and number of organ dysfunctions.^{10, 14} The benefits we have shown are in line with findings from studies on animals, isolated vascular smooth muscles, and inflammatory cells and on healthy volunteers challenged with endotoxin.⁴ Indeed, studies consistently showed that corticosteroids improved vessels' contractility and haemodynamics; prevented inflammatory cells' recruitment, proliferation, and release of pro-inflammatory mediators; and improved survival from all types of animal models of sepsis.⁴ Finally, there was no evidence of increased rates of gastroduodenal bleeding, superinfections, or hyperglycaemia associated with the use of corticosteroids.

There were differences between the six trials conducted after 1992. One trial included both severe sepsis and septic shock,¹³ whereas the others included only septic shock. One trial allowed concomitant therapies with anti-thrombin III or intravenous polyclonal immunoglobulins,¹⁰ and the others did not. The time on shock before randomisation was also different: one trial included only early septic shock,¹² two included late septic shock,^{9, 11} and two included both early and late septic shock.^{10, 14}

Strengths of study

Because of our comprehensive search strategy, omission of important trials seems unlikely. We included 16 trials, but the outcomes foreseen for this review were not available in one crossover trial.¹⁴ This trial showed short term improved haemodynamic and immune outcomes with a low dose of hydrocortisone. We considered it acceptable in a meta-analysis to pool the results from the 15 remaining trials. We converted outcome measures corresponding to censored data into dichotomous variables—that is, proportion of patients with an event after one and four weeks or in the intensive care unit or at hospital discharge.

What is already known

Short courses of high dose corticosteroids do not affect mortality from severe sepsis and septic shock

Long courses of low dose corticosteroids improve systemic haemodynamics and reduce the time on vasopressor treatment

What this paper adds

Long courses of low dose corticosteroids reduce mortality at 28 days, in intensive care units, and in hospital

Long courses of low dose corticosteroids do not significantly alter the risk of gastroduodenal bleeding, superinfections, or hyperglycaemia

Recommendations

We cannot provide definite recommendations for the selection of patients who might most benefit from corticosteroid. Separate data for adrenal insufficiency were available in only two studies.^{9, 12} However, different definitions for adrenal insufficiency were used. In the first trial, too few patients had adrenal insufficiency to draw any conclusion.⁹ In the second trial, a benefit from corticosteroids was shown only in patients with a cortisol increase after adrenocorticotropin hormone ≤ 248 nmol/l.¹² The weight of this trial in the meta-analysis was about 70%. Until there is further research on optimising diagnostic testing of adrenal insufficiency in patients with septic shock, corticosteroids should be given only to patients with a random cortisol concentration ≤ 414 nmol/l (that is, absolute adrenal insufficiency) or a cortisol response to adrenocorticotropin hormone ≤ 248 nmol/l (that is, relative adrenal insufficiency).³⁶

In conclusion, hydrocortisone (or equivalent) should be given to patients with septic shock immediately after they undergo an adrenocorticotropin hormone test, at a dose of 200-300 mg, and should be continued for 5-11 days, only when absolute or relative adrenal insufficiency is present.

A longer version of this review has been published in the Cochrane Library.³⁷

Contributors: All authors were involved in study concept, design, and critical revision for important intellectual content. DA, PEB, JB, DK, and YK were responsible for acquisition of data. DA, PEB, JB, and DK analysed and interpreted the data. DA and EB drafted the review. DA is guarantor.

Funding: Hôpital Raymond Poincaré, Garches, France. UK Department for International Development.

Competing interests: Authors of this review have been involved in randomised controlled trials of low dose hydrocortisone that are included in this review.

Ethical approval: Not required.

- Angus D, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29:1303-10.
- Rangel-Frausto MS, Pittet D, Hwang T, Woolson RF, Wenzel RP. The dynamics of disease progression in sepsis: Markov modeling describing the natural history and the likely impact of effective antiseptic agents. *Clin Infect Dis* 1998;27:185-90.
- Anname D, Aegerter P, Jars-Guineestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Réa Network. *Am J Resp Crit Care Med* 2003;168:165-72.
- Anname D, Cavaillon JM. Corticosteroids in sepsis: from bench to bedside? *Shock* 2003;20:197-207.
- Anname D, Sébille V, Troché G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotrophin. *JAMA* 2000;283:1038-45.
- Meduri GU, Chrousos GP. Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? *Chest* 1998;114:355-60.
- Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. *Crit Care Med* 1995;23:1294-303.
- Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. *Crit Care Med* 1995;23:1430-9.

- 9 Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. *Crit Care Med* 1998;26:645-50.
- 10 Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. *Crit Care Med* 1999;27:723-32.
- 11 Chawla K, Kupfer Y, Tessler S. Hydrocortisone reverses refractory septic shock. *Crit Care Med* 1999;27:A33.
- 12 Annane D, Seville V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002;288:862-71.
- 13 Yildiz O, Doganay M, Aygen B, Guven M, Keleutimur F, Tutuu A. Physiologic-dose steroid therapy in sepsis. *Crit Care* 2002;6:251-9.
- 14 Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. *Am J Resp Crit Care Med* 2003;167:512-0.
- 15 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* 1992;20:864-74.
- 16 Clarke M, Oxman A, eds. *Cochrane reviewers' handbook 4.2.0* [updated March 2003]. In: The Cochrane Library. Issue 3. Chichester: John Wiley, 2003.
- 17 Juni P, Altman DG, Egger M. Systematic reviews in healthcare: assessing the quality of controlled clinical trials. *BMJ* 2001;323:42-6.
- 18 Hahn EO, Houser HB, Rammelkamp CH Jr, Denny FW, Wannamaker LW. Effect of cortisone on acute streptococcal infections and poststreptococcal complications. *J Clin Invest* 1951;30:274-81.
- 19 Wagner HN, Bennett IL, Lasagna L, Cluff LE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. *Bull Johns Hopkins Hosp* 1955;98:197-215.
- 20 Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. *JAMA* 1963;183:462-5.
- 21 Rogers J. Large doses of steroids in septic shock. *Br J Urol* 1970;42:742.
- 22 Thompson WL, Gurley HT, Lutz BA, Jackson DL, Kvols LK, Morris IA. Inefficacy of glucocorticoids in shock (double-blind study). *Clin Res* 1976;24:258A.
- 23 Klastersky J, Cappel R, Debusscher L. Effectiveness of betamethasone in management of severe infections. A double-blind study. *N Engl J Med* 1971;284:1248-50.
- 24 Schumer W. Steroids in the treatment of clinical septic shock. *Ann Surg* 1976;184:333-41.
- 25 McKee JL, Finlay WE. Cortisol replacement in severely stressed patients. *Lancet* 1983;1:484.
- 26 Hughes GS Jr. Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. *Life Sci* 1984;35:2319-26.
- 27 Lucas C, Ledgerwood A. The cardiopulmonary response to massive doses of steroids in patients with septic shock. *Arch Surg* 1984;119:537-41.
- 28 Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. *N Engl J Med* 1984;311:1137-43.
- 29 Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd. Early steroid therapy for respiratory failure. *Arch Surg* 1985;120:536-40.
- 30 Bone RG, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. *N Engl J Med* 1987;317:653-8.
- 31 Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. *N Engl J Med* 1987;317:659-65.
- 32 Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. *Am Rev Resp Dis* 1988;138:62-8.
- 33 Slusher T, Gbadero D, Howard C, Lewison L, Giroir B, Toro L, et al. Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. *Ped Infect Dis J* 1996;15:579-83.
- 34 Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 1998;280:159-65.
- 35 Rothwell PM, Udawadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. *Lancet* 1991;337:582-3.
- 36 Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. *N Engl J Med* 2003;348:727-34.
- 37 Annane D, Bellissant E, Bollaert P, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating severe sepsis and septic shock. *Cochrane Database Syst Rev* 2004;(1):CD002243.

(Accepted 16 June 2004)

doi 10.1136/bmj.38181.482222.55

Critical Care Department, Université de Versailles Saint-Quentin en Yvelines, Assistance Publique-Hôpitaux de Paris, Hôpital Raymond Poincaré, Garches 92380, France

Djillali Annane *professor of intensive care medicine*

Clinical Investigation Centre, INSERM 0203, Université de Rennes 1, Centre Hospitalier Universitaire, Hôpital de Pontchaillou, Rennes 35033, France

Eric Bellissant *professor of clinical pharmacology*

Critical Care Department, Université de Nancy 1, Centre Hospitalier Universitaire, Hôpital Central, Nancy 54000, France

Pierre Edouard Bollaert *professor of intensive care medicine*

Institut für Anaesthesiology, Klinikum der Universität München, Munich, 81366, Germany

Josef Briegel *professor of anaesthesiology and intensive care medicine*

Intensive Care Unit, Charité-Campus Virchow Clinic, Berlin, 13353, Germany

Didier Keh *attending physician*

Division of Pulmonary and Critical Care Medicine, Maimonides Medical Centre, Brooklyn, New York, NY 11219, USA

Yizhak Kupfer *attending physician*

Correspondence to: D Annane djillali.annane@rpc.ap-hop-paris.fr